Johnson & Johnson earnings expected to decline in Q3
JNJ•Johnson & Johnson is expected to report third-quarter revenue of $25.28 billion and adjusted EPS of $2.54, down from $2.80 a year earlier. Revenue is expected to rise from $23.99 billion.
1. Q3 expectations
Johnson & Johnson is expected to report third-quarter results before the bell, with investors watching for a rebound in its medtech unit. Analysts expect revenue of $25.28 billion and adjusted EPS of $2.54, compared with $23.99 billion in revenue and EPS of $2.80 a year earlier.
2. Recent performance
Last quarter, the company beat estimates on strong pharmaceutical sales, while its Abiomed heart pump business saw sales decline following a critical UK study. Johnson & Johnson has met or surpassed EPS and revenue estimates for at least eight consecutive quarters.
